← All stocks

Protalix BioTherapeutics, Inc.

PLX Net selling

CIK 0001006281 #3972 in the set updated 19 Sep 2026

Bought (120 mo)

$851.31K

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$2.88M

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$2.88M

4 of 4 sales

Net

−$2.03M

−$2.03M against sales at will

By person

14 insiders · 12 transactions

13.4×

Dror Bashan holds 13.4 times base salary in stock. $5.40M of shares against $401.84K in salary for 2025.

Salary from the company's own proxy. The shares are what Dror Bashan last reported holding, valued at $1.81, the price Common Stock was last bought or sold at on the open market here, on 19 Dec 2025.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Dexcel Pharma Technologies Ltd. entity

10% owner

—

$2.09M (2)

−$2.09M

3,637,314

4.51%

$6.58M

−20.2%

Camber Capital Management LLC entity

10% owner

—

$792.00K (1)

−$792.00K

10,775,000

13.37%

$19.50M

−18.8%

Schwartz Aharon

Director

$516.96K (3)

—

+$516.96K

310,500

0.3854%

$562.01K

—

Bashan Dror

PRESIDENT AND CEO

$293.84K (4)

—

+$293.84K

2,980,861

3.70%

$5.40M

+565.5%

Manor Moshe

President & CEO

$40.50K (1)

—

+$40.50K

50,000

0.0621%

$90.50K

—

Bar-Shalev Amos

Director

—

$314.16 (1)

−$314.16

7,500

0.0093%

$13.58K

+4,364%

Rubin Eyal

Sr. VP and CFO

—

915,156

1.14%

$1.66M

+271.8%

Naos Yaron

Sr. VP & COO

—

225,817

0.2803%

$408.73K

+1,576%

Hayon Yael

VP, Research & Development

—

35,115

0.0436%

$63.56K

—

Forster Eliot

Director

—

7,500

0.0093%

$13.58K

—

Melincoff Gwen A

Director

—

7,500

0.0093%

$13.58K

—

Boudes Pol F

Director

—

7,500

0.0093%

$13.58K

—

Elze Christian

Director

—

7,500

0.0093%

$13.58K

—

Ben Zvi Shmuel

Director

—

7,500

0.0093%

$13.58K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 72

Amendments (4/A) skipped 3

Filings about a different issuer 0

Unreadable filings 0

Joint filings 1

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 4

Transactions with no price 0

Shares from compensation/vesting 3,313,387

Sales filed before the plan box existed 3

History held since 16 Sep 2016